Hospital

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Why is this woman in opioid withdrawal despite high dose methadone administration?

A newly-developed machine learning system may help act as an alert system for potential adverse effects from drug-drug interactions.

Cefiderocol (Fetroja, Shionogi) is indicated for adults with complicated urinary tract infections, including kidney infections caused by Gram-negative pathogens, who have limited or no alternative treatment options.

According to the affiliation agreement, the Institute for Safe Medication Practices will be an ECRI Institute subsidiary when the transaction closes in January, 2020.

Centers for Disease Control and Prevention warns the time for action is now in the "post-antibiotic era."

Receiving a flu shot before a heart bypass surgery can stop inflammation throughout the body and possibly lead to a healthier recovery, according to a preliminary study presented at the American Heart Association’s Scientific Sessions in Philadelphia, Pennsylvania.

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

With expanding pharmacy practice, it is time to explore conflict management, and its necessity in this current climate.

One health care organization has taken their flu vaccination efforts to the next level, by vaccinating the majority of its 12,000 employees, during a 1-day event called #HitMeWithYourFluShot.

With this approval, luspatercept-aamt (Reblozyl, Celgene) is the first FDA-approved erythroid maturation agent for anemia in beta thalassemia

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

Omeprazole magnesium, amoxicillin, and rifabutin (Talicia, RedHill Biopharma) is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Top news of the day from across the health care landscape.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.

The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.

Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.

Attendees of a session on operating a long-term-care (LTC) pharmacy received tips on key metrics, technology advancements, and meeting customer needs, during the National Community Pharmacists Association (NCPA) 2019 Annual Convention.

Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.

Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1

Top news of the day from across the health care landscape.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.